TECHNOLOGY DEVELOPMENT

 

Mount Tam Biotechnologies is an emerging specialty biopharmaceutical company focused on the development of novel, breakthrough therapeutics for the treatment of autoimmune disorders. Its facilities are located at the Buck Institute in the San Francisco Bay Area. 

 

Mount Tam has partnered with the world-renowned Buck Institute for Research on Aging through a worldwide exclusive licensing and collaboration agreement. The assets, which are focused on autoimmune diseases, are highly target-specific polyketides—a class of compounds with an extremely successful track record with the F.D.A. drug approval process. The assets are supported by intellectual property consisting of over 45 worldwide issued patents and patent applications, including composition of matter, manufacturing and therapeutic area applications. 

 

Mount Tam is applying its first and most advanced asset, TAM-01, to the Investigational New Drug (IND) application phase of the FDA. It has already completed extensive non-GLP pre-clinical development. The primary focus is to develop TAM-01 for the treatment of systemic lupus erythematosus (SLE) in an expanding orphan drug market. Mount Tam will use the R&D conducted on TAM-01 as the core science for additional assets, including its second product known as TAM-02, which is focused on multiple sclerosis (MS).

 

For more information, click on the related subject below: